Despite this clinical uncertainty, analysis of malignant melanoma patients responsive to anti-CTLA-4 ipilimumab therapy who were monitored over a period of more than 10 years revealed that they appear to have gained long-term protection, supporting the possibility of a post-tumour vaccine effect [58]. This evidence concerns the gene CTLA4 and neoplasm.